The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Headwaters Capital sees deep value in Bio-Techne as academic cuts weigh on shares. Learn why this life sciences leader could ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...